Marks Group Wealth Management Inc boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 433.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,281 shares of the company’s stock after purchasing an additional 36,789 shares during the quarter. Marks Group Wealth Management Inc’s holdings in AstraZeneca were worth $3,050,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AZN. Anchor Investment Management LLC bought a new stake in shares of AstraZeneca during the 4th quarter worth $26,000. Compagnie Lombard Odier SCmA bought a new stake in AstraZeneca during the fourth quarter valued at about $27,000. Nemes Rush Group LLC boosted its holdings in AstraZeneca by 375.6% during the third quarter. Nemes Rush Group LLC now owns 428 shares of the company’s stock valued at $29,000 after acquiring an additional 338 shares during the period. LWM Advisory Services LLC acquired a new stake in shares of AstraZeneca in the third quarter valued at about $35,000. Finally, Arlington Trust Co LLC bought a new position in shares of AstraZeneca in the fourth quarter worth about $37,000. Institutional investors and hedge funds own 20.35% of the company’s stock.
AstraZeneca Trading Up 1.0 %
Shares of AZN opened at $70.85 on Wednesday. The stock’s 50-day moving average price is $66.62 and its 200 day moving average price is $65.92. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $219.67 billion, a price-to-earnings ratio of 36.90, a P/E/G ratio of 1.29 and a beta of 0.50. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $76.56.
AstraZeneca Increases Dividend
The firm also recently declared a Semi-Annual dividend, which was paid on Monday, March 25th. Shareholders of record on Friday, February 23rd were issued a $0.965 dividend. This represents a yield of 2.3%. The ex-dividend date of this dividend was Thursday, February 22nd. This is a positive change from AstraZeneca’s previous Semi-Annual dividend of $0.47. AstraZeneca’s payout ratio is 100.52%.
Analysts Set New Price Targets
Several analysts recently weighed in on the company. Jefferies Financial Group downgraded AstraZeneca from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Finally, Morgan Stanley started coverage on shares of AstraZeneca in a research report on Tuesday, January 23rd. They set an “overweight” rating on the stock. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $80.00.
Check Out Our Latest Report on AstraZeneca
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- Best Aerospace Stocks Investing
- GE Aerospace is Ready for Liftoff After Strong Earnings
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- The Bottom is in For Tesla: Read This Before Buying the Bounce
- Quiet Period Expirations Explained
- 3 Technologies to Challenge NAND Flash Dominance in AI
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.